BioScrip Inc to Post FY2018 Earnings of ($0.22) Per Share, Barrington Research Forecasts (BIOS)
BioScrip Inc (NASDAQ:BIOS) – Research analysts at Barrington Research increased their FY2018 earnings estimates for shares of BioScrip in a research note issued to investors on Monday. Barrington Research analyst M. Petusky now expects that the company will earn ($0.22) per share for the year, up from their previous forecast of ($0.23).
Several other research analysts have also commented on the stock. Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub upgraded shares of BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 price objective on shares of BioScrip and gave the company a “buy” rating in a research note on Thursday, December 21st. Finally, ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. BioScrip presently has an average rating of “Buy” and an average price target of $3.63.
BioScrip (NASDAQ:BIOS) last released its earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same quarter in the previous year, the company earned ($0.12) earnings per share. The business’s revenue was down 11.5% on a year-over-year basis.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of BioScrip during the third quarter worth about $114,000. Captrust Financial Advisors bought a new position in shares of BioScrip during the second quarter worth about $123,000. Voya Investment Management LLC grew its holdings in shares of BioScrip by 41.4% during the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after buying an additional 14,867 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of BioScrip during the third quarter worth about $153,000. Finally, Skylands Capital LLC bought a new position in shares of BioScrip during the third quarter worth about $272,000. 84.63% of the stock is currently owned by institutional investors.
In related news, CEO Daniel E. Greenleaf bought 15,000 shares of BioScrip stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the acquisition, the chief executive officer now owns 31,000 shares in the company, valued at $62,930. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.80% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “BioScrip Inc to Post FY2018 Earnings of ($0.22) Per Share, Barrington Research Forecasts (BIOS)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/10/bioscrip-inc-to-post-fy2018-earnings-of-0-22-per-share-barrington-research-forecasts-bios.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.